VACH
Voyager Acquisition Corp.10.57
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
334.28MP/E (TTM)
35.23Basic EPS (TTM)
0.30Dividend Yield
0%Recent Filings
8-K
SPAC approves Veraxa deal
Voyager Acquisition Corp shareholders approved the business combination with Veraxa Biotech AG on March 12, 2026, but 99.67% of Class A shares redeemed, leaving ~$885,556 in trust and 82,685 shares converting. Closing awaits Nasdaq listing and customary conditions. Massive redemptions gut cash reserves.
10-K
FY2025 results
Voyager Acquisition Corp, a blank check company, posted FY2025 net income of $8.99M driven entirely by $10.76M in trust income, up from $4.14M in FY2024, while operating expenses hit $1.79M amid heightened public company costs. Trust assets swelled to $269.9M at $10.67/share by December 31, 2025 from $259.1M at $10.24/share, reflecting steady accretion. No revenue or operations yet; cash outside trust dwindled to $182K with a $1.1M working capital deficit. Signed Veraxa Biotech deal targets Q1 2026 close at ~$1.35B valuation, but faces shareholder approval risks. No quarterly breakdowns disclosed. Sponsor covers liquidity gaps. Yet SPAC deals often drag.
8-K
VERAXA approves SPAC merger
VERAXA Biotech shareholders approved the merger with Veraxa Biotech Holding AG and issuance of new shares to Voyager Acquisition Corp (NASDAQ: VACH) at their EGM on February 27, 2026. This clears a key hurdle for the SPAC deal, paving the way for Nasdaq listing under VRXA—pending Voyager shareholder nod. Closing hinges on that vote.
8-K
BCA amended, consideration up 3.8%
Voyager Acquisition Corp. amended its business combination agreement with Veraxa Biotech AG on February 2, 2026, boosting aggregate merger consideration to $1.35B from $1.3B. Sponsor will forfeit 200,000 Class B shares and 400,000 warrants at closing, with equivalents issued to Veraxa shareholders. Waiver enables proposing removal of $5M net tangible asset requirement. Deal advances amid redemptions risk.
10-Q
Q3 FY2025 results
Voyager Acquisition Corp posted Q3 net income of $2.4M, up from $1.3M y/y, fueled by $2.8M Trust income versus $1.7M prior (derived); YTD net income hit $7.3M from $1.2M y/y on $8.2M Trust income. G&A fell to $406K from $529K y/y while operating loss held steady. Trust swelled to $267.3M at $10.56/share, cash at $252K outside; no debt. Signed April 2025 business combination with Veraxa Biotech via two-step merger into Swiss PubCo. Sponsor may fund working capital. Yet failure to close by August 2026 triggers liquidation.
BAYA
Bayview Acquisition Corp
11.63-0.01
HYAC
Haymaker Acquisition Corp. 4
11.34+0.04
LOKV
Live Oak Acquisition Corp. V
10.27+0.02
MCAG
Mountain Crest Acquisition Corp
12.29+0.00
PACH
Pioneer Acquisition I Corp
10.11+0.01
SVCC
Stellar V Capital Corp.
10.38+0.00
TACH
Titan Acquisition Corp.
10.24-0.01
TDAC
Translational Development Acqui
10.42+0.00
YHNA
YHN Acquisition I Limited
10.65+0.00
YOTA
Yotta Acquisition Corporation
2.00+0.00